1. Skip to content

Category: Featured Story

  • FDA Approval of Gefitinib for Lung Cancer Could Bring New Treatment to Mesothelioma Patients

    The U.S. Food and Drug Administration announced it has approved Iressa (gefitinib) for the initial treatment of metastatic epidermal growth factor receptor–positive (EGFR-positive) non–small-cell lung cancer (NSCLC). This approval is good news for the mesothelioma community as it brings a new option for treatment to mesothelioma patients. The drug, an EGFR tyrosine kinase inhibitor (TKI), …

    Label: Featured Story

    Posted on Monday, Jul 20, 2015
  • Biomarker Improves Survival, Effectiveness of Chemotherapy in Mesothelioma Patients

    Researchers’ efforts to find a treatment that can halt mesothelioma cancer growth have continually been thwarted by the cancers’ ability to outwit medicines thrown at them. Turning to personalized medicine, teams of researchers have shifted their focus to finding a protein or biomarker unique to mesothelioma that can be targeted to improve the effectiveness of …

    Label: Featured Story

    Posted on Thursday, Jul 16, 2015
  • Researchers Report BAP1 Biomarker May be Predictive of Mesothelioma

    For years, researchers have struggled to find a biomarker common to mesothelioma patients that can be targeted to quickly diagnose the deadly cancer. Now, Italian researchers report the BAP1 protein could be just the link needed to help distinguish between benign and malignant mesotheliomas. Malignant mesothelioma is an asbestos-caused cancer that affects the lining of …

    Label: Featured Story

    Posted on Thursday, Jul 9, 2015
Load More News Load Older News